Peptide name : mtp1

Source/Organism : Synthetic

Linear/Cyclic : Linear

Chirality : L

Peptide length: 12

C-terminal modification: Linear

N-terminal modification : Free

Non-natural peptide information:

Assay type : MTS assay

Assay time : 24-h

Activity : 33.6% decrease in cell viability at 10 μM

Cell line : MDA-MB-231

Cancer type : Breast Cancer

Other activity : Anticancer

Amino acid composition bar chart :

Molecular mass : 1438.4113 Dalton

Aliphatic index : 0.083

Instability index : -3.3583

Hydrophobicity (GRAVY) : -1.758

Isoelectric point : 4.05

Charge (pH 7) : -3.2337

Aromaticity : 16.66

Molar extinction coefficient (cysteine, cystine): (0, 0)

Hydrophobic/hydrophilic ratio : 0.5

hydrophobic moment : -0.251

Missing amino acid : C,F,H,I,K,L,M,N,P,Q,V,Y

Most occurring amino acid : D

Most occurring amino acid frequency : 3

Least occurring amino acid : G

Least occurring amino acid frequency : 1

Secondary structure fraction (Helix, Turn, Sheet): (16., 41., 33.)

SMILES Notation: C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)O)[C@@H](C)O)[C@@H](C)O

1 : Rauff R, et al. Peptides Targeting RNA m6 A Methylations Influence the Viability of Cancer Cells. ChemMedChem. 2023; 18:e202200549. doi: 10.1002/cmdc.202200549

Paper title : Peptides Targeting RNA m6 A Methylations Influence the Viability of Cancer Cells.

Doi : https://doi.org/10.1002/cmdc.202200549

Abstract : N6-methyladenosine (m6 A) is the most abundant nucleotide modification observed in eukaryotic mRNA. Changes in m6 A levels in transcriptome are tightly correlated to expression levels of m6 A methyltransferases and demethylases. Abnormal expression levels of methyltransferases and demethylases are observed in various diseases and health conditions such as cancer, male infertility, and obesity. This research explores the efficacy of m6 A-modified RNA as an anticancer drug target. We discovered a 12-mer peptide that binds specifically to m6 A-modified RNA using phage display experiments. Our fluorescence-based assays illustrate the selected peptide binds to methylated RNA with lower micromolar affinity and inhibit the binding of protein FTO, a demethylase enzyme specific to m6 A modification. When cancer cell lines were treated with mtp1, it led to an increase in m6 A levels and a decrease in cell viability. Hence our results illustrate the potential of mtp1 to be developed as a drug for cancer.